We are live on
!
Find out more
CCM
Catapult Capital Management Portfolio holdings
AUM
$265M
1-Year Est. Return
21.83%
This Fund
S&P 500
This Quarter
Est. Return
+5.74%
1 Year Est. Return
+21.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$696M
AUM Growth
-$122M
(-15%)
Cap. Flow
-$135M
Cap. Flow
% of AUM
-19.45%
Top 10 Holdings %
Top 10 Hldgs %
23.76%
Holding
329
New
119
Increased
34
Reduced
64
Closed
111
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoetis
ZTS
|
+$23.2M |
| 2 |
PepsiCo
PEP
|
+$13.1M |
| 3 |
AbbVie
ABBV
|
+$10.1M |
| 4 |
Elevance Health
ELV
|
+$9.59M |
| 5 |
Abbott
ABT
|
+$8.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$22.4M |
| 2 |
Pfizer
PFE
|
+$18M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$13.1M |
| 4 |
Pediatrix Medical
MD
|
+$11.2M |
| 5 |
Danaher
DHR
|
+$11.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.68% |
| 2 | Consumer Discretionary | 8.46% |
| 3 | Industrials | 7.26% |
| 4 | Consumer Staples | 5.08% |
| 5 | Communication Services | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Zoetis
ZTS
$31.9B
| $23.5M | 3.37% |
+486,665
| New | +$23.2M |
|
2
CVS Health
CVS
$134B
| $20.7M | 2.97% |
196,947
+80,336
| +69% | +$8.21M |
|
3
CALL
iShares Russell 2000 ETF
IWM
$80.2B
| $18.7M | 2.69% |
+150,000
| New | +$18.7M |
|
|
4
AbbVie
ABBV
$455B
| $18.1M | 2.61% |
270,000
+155,000
| +135% | +$10.1M |
|
5
Edwards Lifesciences
EW
$50B
| $17.2M | 2.48% |
725,718
+125,718
| +21% | +$2.84M |
|
|
SHPG
6
DELISTED
Shire pic
SHPG
| $15.3M | 2.19% |
63,255
+18,255
| +41% | +$4.53M |
|
7
DaVita
DVA
$15.3B
| $13.9M | 2% |
175,100
+33,774
| +24% | +$2.77M |
|
|
8
PepsiCo
PEP
$191B
| $12.8M | 1.84% |
+137,074
| New | +$13.1M |
|
9
Universal Health Services
UHS
$9.88B
| $12.8M | 1.84% |
90,000
+40,000
| +80% | +$5.01M |
|
10
McKesson
MCK
$101B
| $12.4M | 1.78% |
55,000
+21,017
| +62% | +$4.86M |
|
|
MNK
11
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $11.6M | 1.67% |
98,715
-106,225
| -52% | -$13.1M |
|
|
ESRX
12
DELISTED
Express Scripts Holding Company
ESRX
| $11.1M | 1.6% |
125,000
+50,000
| +67% | +$4.37M |
|
|
13
Elevance Health
ELV
$81.6B
| $9.85M | 1.42% |
+60,000
| New | +$9.59M |
|
|
14
Abbott
ABT
$183B
| $8.59M | 1.23% |
+175,000
| New | +$8.4M |
|
15
Gilead Sciences
GILD
$163B
| $8.29M | 1.19% |
+70,800
| New | +$7.74M |
|
16
Meta Platforms (Facebook)
META
$1.37T
| $6.85M | 0.98% |
79,880
+1,210
| +2% | +$98.8K |
|
17
Humana
HUM
$44B
| $6.7M | 0.96% |
35,000
-15,000
| -30% | -$2.78M |
|
|
18
PUT
Humana
HUM
$44B
| $6.7M | 0.96% |
+35,000
| New | +$6.5M |
|
19
Thermo Fisher Scientific
TMO
$214B
| $6.49M | 0.93% |
+50,000
| New | +$6.52M |
|
|
AET
20
DELISTED
Aetna Inc
AET
| $6.37M | 0.92% |
+50,000
| New | +$5.71M |
|
|
AET
21
PUT
DELISTED
Aetna Inc
AET
| $6.37M | 0.92% |
+50,000
| New | +$5.71M |
|
22
McDonald's
MCD
$191B
| $6.29M | 0.9% |
66,200
-10,812
| -14% | -$1.05M |
|
|
ADPT
23
DELISTED
Adeptus Health Inc
ADPT
| $6.17M | 0.89% |
65,000
+15,000
| +30% | +$1.03M |
|
|
24
Teva Pharmaceuticals
TEVA
$41.2B
| $6.08M | 0.87% |
102,831
-363,908
| -78% | -$22.4M |
|
25
Perrigo
PRGO
$1.43B
| $5.92M | 0.85% |
+32,057
| New | +$6.11M |
|
Similar funds
LOCB
AF
TCOTO
DCM
SCA
LPVHS
ATC
TFF
Catapult Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Catapult Capital Management held 329 positions worth $696M, down 15% from $818M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Catapult Capital Management withdrew a net $135M in Q2 2015, closing 111 positions and reducing 64 holdings. Its most notable exit was Pfizer, an estimated $18M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 33% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Catapult Capital Management opened a new position in Zoetis worth $23.5M.
- Catapult Capital Management's largest Q2 2015 buy was Zoetis: 486,665 shares worth $23.5M.
- Catapult Capital Management added most to AbbVie in Q2 2015, an estimated $10.1M increase.
- Catapult Capital Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $22.4M.
- Catapult Capital Management fully exited Pfizer in Q2 2015, selling an estimated $18M.
- Catapult Capital Management's ten largest holdings make up 24% of its $696M portfolio in Q2 2015.
- Catapult Capital Management opened 119 new positions and closed 111 in Q2 2015.
- Catapult Capital Management's portfolio value fell 15% quarter-over-quarter to $696M.
Based on Catapult Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.